Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that CTI has received the remaining $5 million from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) available under the existing loan agreement that was established in March 2013. Further information with respect to this loan with Hercules will be available in a Current Report on Form 8-K that will be filed by CTI with the Securities and Exchange Commission.
About Cell Therapeutics, Inc.
Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.
About Hercules Technology Growth Capital, Inc.
Hercules Technology Growth Capital, Inc., (NYSE: HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $3.9 billion to over 250 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. For more information please visit www.htgc.com, or call 650-289-3060.